通过对上市公司与其控股母公司的相互影响分析,结合桂林三金集团及其上市公司的经营活动与财务管理状况的分析,发现规模不大的集团往往因为只控制一家上市公司而在其他非上市业务板块表现欠佳,通常需要从充分发挥集团调控功能、加快推动其他医药产品开发、适当延伸产业链、拓宽集团融资渠道等方面着手解决问题。 Through the analysis of the interaction between listed companies and their parent holding companies and the analysis of the operating activities and financial management status of Guilin Sanjin Group and its listed companies, it was found that the small-sized ones tend to be listed on other non-listed companies because they only control one listed company The poor performance of the business segment usually requires solving problems in terms of giving full play to the regulatory functions of the Group, accelerating the development of other pharmaceutical products, extending the industrial chain as appropriate, and broadening the Group’s financing channels.